Results 21 to 30 of about 2,876 (190)

Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension [PDF]

, 2015
Background A post-hoc analysis was performed on the data from a 54 weeks phase III study (ClinicalTrials.gov identifier: NCT00923091) to measure changes in the health-related quality of life (HRQoL) of 2,690 patients aged ≥18 with moderate-to-severe ...
Brazier, J.E., da Silva, P.M., Guest, J.F., Haag, U., Soro, M.   +4 more
core   +2 more sources

Antagonistas da angiotensina II: experiência clínica com o tratamento da hipertensão, prevenção de desfechos cardiovasculares e proteção renal na nefropatia diabética e proteinúria [PDF]

, 2006
Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago. During this period they were evaluated not only in terms of efficacy and safety but also in several large studies with clinical outcomes. They are efficacious in
Gavras, Haralambos, Ribeiro, Artur Beltrame   +1 more
core   +4 more sources

Evaluation of the relative bioavailability between two formulations of olmesartan medoxomil 40mg, in orodispersible tablet form and coated tablet form, in healthy participants of both sexes [PDF]

Brazilian Journal of Pharmaceutical Sciences
The objective of this study was to verify whether the test formulation of olmesartan medoxomil, in orodispersible tablet form, administered with water (treatment B) and without water (treatment C), presents a rate and extent of absorption equivalent to ...
Guilherme Guimarães de Souza, Iram Moreira Mundim, Franciely Jesus Guedes, Laura Moreira Rezeck, Vanessa Martins Vilela, Karini Bruno Bellorio, Leonardo de Souza Teixeira, Rafael Paletta da Silva   +7 more
doaj   +1 more source

IN SILICO EVALUATION OF ANGIOTENSIN II RECEPTOR ANTAGONIST’S PLASMA PROTEIN BINDING USING COMPUTED MOLECULAR DESCRIPTORS [PDF]

, 2014
The discovery of new pharmacologically active substances and drugs modeling led to necessity of predicting drugs properties and its ADME data. Angiotensin II receptor antagonists are a group of pharmaceuticals which modulate the renin-angiotensin ...
Jadranka Odović, Jasna Trbojević-Stanković   +1 more
core   +1 more source

Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J) [PDF]

, 2006
Background The coexistence of type 2 diabetes mellitus and hypertension increases the risk of cardiovascular diseases. The U.K. Prospective Diabetes Study has shown that blood pressure control as well as blood glucose control is efficient for prevention ...
Ryuzo Kawamori, Hiroyuki Daida, Yasushi Tanaka, Katsumi Miyauchi, Akira Kitagawa, Dobun Hayashi, Junji Kishimoto, Shunya Ikeda, Yutaka Imai, Tsutomu Yamazaki, M Epstein, E Grossman, American Diabetes Association, UK Prospective Diabetes Study Group, L Hansson, American Diabetes Association, AV Chobanian, Guideline Committee, H Yki-Järvinen, L Hansson, Dahlöf Björn, PB Timmermann, B Dahlöf, L Hansson, The Norwegian Multicenter Study Group, First International Study of Infarct Survival Collaborative Group, J Tumoliehto, RO Estacio, M Epstein, D Giugliano, CD Furberg, P Tatti, M Alderman, RP Byington, M Pahor, M Pahor   +35 more
core   +2 more sources

Is the newest angiotensin‐receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta‐analysis

The Journal of Clinical Hypertension, 2021
Angiotensin‐receptor blockers are often considered insufficiently efficacious in reducing blood pressure. However, newer angiotensin‐receptor blockers may be more effective than the older ones.
Ji‐Guang Wang, Miao Zhang, Ying‐Qing Feng, Chang‐Sheng Ma, Tzung‐Dau Wang, Zhi‐Ming Zhu, Kazuomi Kario   +6 more
doaj   +1 more source

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, EarlyView.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension

Pharmaceuticals, 2009
Background: Combination therapy with antihypertensive agents utilises different mechanisms of action and may be responsible for a more effective decrease in blood pressure.
Menco G. Niemeijer, Ton J. Cleophas
doaj   +1 more source

Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers : a randomized study [PDF]

, 2013
Background: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are renoprotective but both may increase serum potassium concentrations in patients with chronic kidney disease (CKD).
A Mimran, A Rastegar, AS Levey, B Pitt, Berta Renedo, BF Palmer, BF Palmer, BL Svarstad, BM Brenner, BS Heran, CE Mogensen, CR Moore, Daniel Serón, DB Mount, DE Morisky, E Espinel, E Porteri, EJ Lewis, EJ Lewis, Eugenia Espinel, FF Hou, G Mancia, G Maschio, GD Sanders, GL Bakris, HH Parving, Iván Gil, J Yasky, Joan Fort, Jorge Joven, K Takaichi, LC Reardon, MJ Fabia, MR Weir, MR Weir, MS Stevens, N El-Sherif, P Sharma, PH Pun, Pilar Suñé, PR Jarman, RA Preston, RS Mckelvie, RT Gansevoort, S De Denus, S Korgaonkar, S Kuriyama, S Omboni, S Oparil, SA Hunt, SP Crispim, SP Ponce, TH Jafar   +52 more
core   +1 more source

Sustainability in Analytical Chemistry Illustrated by Pharmaceutical Nitrosamine Testing

ELECTROPHORESIS, Volume 47, Issue 2, Page 175-184, February 2026.
ABSTRACT Following the valsartan scandal in 2018, the testing of drug substances and drug products for N‐nitrosamines has become a critical and mandatory quality control measure. The European Pharmacopoeia chapter 2.5.42 currently describes three analytical methods for this purpose: HPLC–MS/MS, GC–MS, and GC–MS/MS.
Felix Bredendiek, Sebastian Schmidtsdorff, Maria Kristina Parr   +2 more
wiley   +1 more source